key: cord-0929744-oaf7pgfh
authors: Blackall, Douglas; Moreno, Raymond; Jin, Justin; Plotinsky, Rachel; Dworkin, Ronald; Oethinger, Margret
title: Performance Characteristics of the Roche Diagnostics cobas Liat PCR System as a COVID-19 Screening Tool for Hospital Admissions in a Regional Health Care Delivery System
date: 2021-09-20
journal: J Clin Microbiol
DOI: 10.1128/jcm.01278-21
sha: a17cfc7a6d1dd31784f4f6b99fe85a699f8ff6a4
doc_id: 929744
cord_uid: oaf7pgfh

The COVID-19 pandemic has required rapid implementation of multiple instrumentation platforms to detect SARS-CoV-2. .

Corporation, Verona, WI). An assessment of the cobas Liat-positive test results is provided in Table 2 . The overall false-positive rate (i.e., screening test positive, confirmatory test negative) was 9.6%, with striking differences between the symptomatic and asymptomatic patient populations. There was significant variability in false-positive rates across the 8-hospital system, ranging from 0% to 17% (data not shown). There was also variability in the false-positive rate depending on the confirmatory testing platform employed: 4.2% for the BD MAX and 15.9% for the Roche cobas 6800. This difference may relate to differing limits of detection for each assay. Of note, there was an early cluster of 4 consecutive false-positive test results at one of the hospitals that was attributed to a leaky test cartridge. These results are not included in this performance assessment. Aside from this, false-positive results were sporadic rather than clustered and were not associated with leaking test cartridges. False-positive rates did not change substantially over the length of the project.

The cobas Liat false-positive rate that we experienced was far higher than that identified in a recent publication (2) . It is also higher than the rate of false-positive results that we might have expected from an Urgent Medical Device Correction issued by Roche Diagnostics Corporation (3). However, it is important to note that another factor played a role: we used the cobas Liat as a SARS-CoV-2 screening tool in a predominantly asymptomatic patient population, which was not the intent of the original EUA for this assay (i.e., use in symptomatic individuals suspected of respiratory viral infection consistent with COVID-19) (4). In a low-prevalence population, a somewhat higher false-positive rate is expected due to a lower predictive value of a positive test. This was largely borne out in differing false-positive rates between symptomatic and asymptomatic patients: 3.8% and 23.9%, respectively.

Despite concern over false-positive cobas Liat results, screening of all new inpatients has had tremendous logistical benefits for our organization. Since 95% of initial cobas Liat tests were negative for SARS-CoV-2 RNA, streamlined patient admissions could ensue without the need for either special segregation or the excessive use of personal protective equipment. Rather, attention was paid to those patients, 5% of the total screened, who initially tested cobas Liat positive. These patients were designated presumptively positive for COVID-19 and were treated as such until the results of confirmatory testing were available (on average, within 9 h of cobas Liat testing, with 95% completed within 24 h).

In conclusion, although the cobas Liat PCR system had a relatively high false-positive rate in our assessment, when used as a screening tool in a predominantly asymptomatic patient population, it has provided improved hospital operational efficiency across our regional health care system. We will continue our 2-stage testing approach for cobas Liat-positive results to gain additional knowledge and understanding of how best to use this molecular technology.

Potential for false results with Roche Molecular Systems, Inc. cobas SARS-CoV-2 & Influenza Test for use on cobas Liat System-letter to clinical laboratory staff, point-of-care facility staff, and health care providers

Clinical performance of the point-of-care cobas Liat for detection of SARS-CoV-2 in 20 minutes: a multicenter study

Roche Diagnostics Corporation. 2021. cobas SARS-CoV-2 & Influenza A/B assay for use under emergency use authorization-potential for invalid or false positive results

US Food and Drug Administration. 2020. Emergency use authorization